Effectiveness of "Medisinstart" - an Open Randomized Controlled Trial of a Newly Developed Pharmacy Service
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,480
- 试验地点
- 67
- 主要终点
- Adherence by Morisky 8-item Medication Adherence Scale (MMAS-8) at 7 weeks
研究概览
简要总结
"Medisinstart" is a new service developed for use in Norwegian pharmacies. It is intended for patients that are about to start a new medicine for a chronic or long-term condition. It is based on research showing that problems with newly prescribed medicines appear rapidly and that a significant portion of patients quickly becomes non-adherent. The service consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine.
The main purpose of this study is to investigate whether "Medisinstart" increases patients' adherence to the prescribed medication. Patients' beliefs about their medicines and their motivation for adherence will also be examined. The study also aims at revealing if "Medisinstart" has additional benefits for the patient, the society and the pharmacies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •First time prescription for a drug belonging to one of the following groups (ATC-code):
- •Dabigatran etexilate (B01AE07)
- •Rivaroxaban (B01AF01)
- •Apixaban (B01AF02)
- •Beta blocking agents (C07)
- •Calcium channel blockers (C08)
- •Agents acting on the renin-angiotensin system (C09)
- •HMG CoA reductase inhibitors (statins) (C10AA)
排除标准
- •Prior use (within the last 3 years) of the drug in question independent of strength, dose and formulation
结局指标
主要结局
Adherence by Morisky 8-item Medication Adherence Scale (MMAS-8) at 7 weeks
时间窗: 7 weeks after dispensing the new medicine
Adherence will be measured by a validated Norwegian translation of the MMAS-8
Adherence by Morisky 8-item Medication Adherence Scale (MMAS-8) at 18 weeks
时间窗: 18 weeks after dispensing the new medicine
Adherence will be measured by a validated Norwegian translation of the MMAS-8
次要结局
- Self reported adherence at 18 weeks(18 weeks after dispensing the new medicine)
- Patients' beliefs about their medicines by Beliefs about Medicines Questionnaire (BMQ) at 18 weeks(18 weeks after dispensing the new medicine)
- Self reported adherence at 7 weeks(7 weeks after dispensing the new medicine)
- Adherence by Medication Possession Ratio (MPR) at 18 weeks(18 weeks after dispensing the new medicine)
- Patients' beliefs about their medicines by Beliefs about Medicines Questionnaire (BMQ) at inclusion(At inclusion)
- Adherence by Medication Possession Ratio (MPR) at 1 year(1 year after dispensing the new medicine)
- Patients' beliefs about their medicines by Beliefs about Medicines Questionnaire (BMQ) at 7 weeks(7 weeks after dispensing the new medicine)